Navigation Links
QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
Date:1/23/2008

NEW YORK, Jan. 23 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Monday January 28, 2008 Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) will replace MGI Pharma, Inc. (Nasdaq: MOGN) in the HealthShares(TM) Composite Index. MGI Pharma is being acquired by Eisai Pharma of Japan (Tokyo, TSE:4523).

Eisai Pharma will replace MGI Pharma in the HealthShares(TM) Cancer Index, and Dr. Reddy's Laboratories, Ltd (NYSE: RDY) will replace MGI Pharma in the HealthShares(TM) Neuroscience Index.

The Composite Index consists of the 80 largest companies by market capitalization that are engaged in healthcare, life sciences and/or biotechnology that are part of the 20 Composite eligible Indexes.

Companies included in the HealthShares(TM) Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers. They generally include those with substantial revenues and significant research and development programs.

Companies included in the HealthShares(TM) Neuroscience Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of neurological and psychiatric disorders including, but not limited to, Alzheimer's, Parkinson's, Huntington's, schizophrenia, anxiety, depression, epilepsy, pain and sleep disorders.

The weightings for Regeneron Pharmaceuticals in the HealthShares(TM) Composite Index, Eisai Pharma in the HealthShares(TM) Cancer Index and Dr. Reddy's Laboratories, Ltd. in the HealthShares(TM) Neuroscience Index will be identical to those of companies being removed from their indexes on the effective date.

About QED International Associates

QEDI International, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at http://www.qedinternational.com


'/>"/>
SOURCE QED International Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tasker Products to Showcase Tasker Blue at International Poultry Expo
2. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
3. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
4. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Carbon offset warning from international team of scientists
6. Palomar and Q-MED AB Enter Into International Distribution Agreement
7. International Association of Fire Fighters (IAFF) Advocates Screening Fire Fighters for Carbon Monoxide Poisoning Using Pulse CO-Oximetry
8. International team identifies 480 genes that control human cell division
9. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
10. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
11. Baxter International Fourth Quarter 2007 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017 The ... at a CAGR of around 7.5% over the ... 2025. Some of the prominent trends that the ... incidences of diseases & graft transplant surgeries and ... Material the market is categorized into immunomodulatory biomaterials, ...
(Date:1/17/2017)... --  Pulmatrix, Inc . (NASDAQ: PULM ), ... to address serious pulmonary diseases, today announced that its ... of CF patients, PUR1900, has been designated as a ... & Drug Administration. Under the QIDP ... of novel drugs against important pathogens, Pulmatrix will receive ...
(Date:1/17/2017)... N.Y. , Jan. 17, 2017  Northwell ... speed the advance of precision cancer research. ... largest health care provider, Northwell Health ... year. Indivumed, GmbH is a Germany ... anti-cancer medical therapies. Together they will greatly expand ...
(Date:1/17/2017)... ... January 17, 2017 , ... NeoTrident, ... provider of learning and performance management systems for high-consequence industries, announced today that ... “In the life sciences industry, organizations must pay much more attention to the ...
Breaking Biology Technology:
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CES® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:12/22/2016)... VIEW, Calif. , Dec. 20, 2016  As part ... levels, 23andMe, the leading personal genetics company, recently released its ... Me . The book focuses on the topics of ... Next Generation Science Standards (NGSS) taught in elementary school classrooms ... second in a series by illustrator Ariana Killoran , ...
(Date:12/19/2016)... BARCELONA , España y TORONTO , 19 ... fusión con Northern Biologics Inc. que permitirá el desarrollo acelerado de ... ensayos clínicos en varios tipos de tumor en 2017, con múltiples ... ... de su clase con objetivo en el factor inhibidor de leucemia ...
Breaking Biology News(10 mins):